烟氯苯丁酯 | 10571-59-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 烟氯苯丁酯
• 中文别名: 尼可氯酯
• 英文名称: p-Chlorphenyl-isopropylcarbinol-nikotinat
• 英文别名: p-Chlorphenyl-isopropylcarbinol-nicotinat；3-pyridinecarboxylic acid 1-(4-chlorophenyl)-2-methylpropyl ester；1-(p-chlorophenyl)-isobutyl nicotinate；nicoclonate；[1-(4-chlorophenyl)-2-methylpropyl] pyridine-3-carboxylate
• CAS: 10571-59-2
• 化学式: C₁₆H₁₆ClNO₂
• 分子量: 289.762
• InChiKey: XPPXHQUWVYMTDM-UHFFFAOYSA-N

物化性质

• 熔点：
  61-62° (Maquenne block); 55-56.5° (Culatti block)
• 沸点：
  390.1±22.0 °C(Predicted)
• 密度：
  1.188±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

文献信息

• GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS
  申请人：South Dakota Board of Regents

  公开号：US20200048305A1

  公开（公告）日：2020-02-13

  The present invention describes compositions containing cholesterol-linker-glutathione conjugates for targeting the brain by overcoming barrier entry to the CNS through the blood brain barrier (BBB), including micelle and liposome forms of such compositions. In addition, methods for treating subjects by administering such compositions are also disclosed.

  本发明描述了含有胆固醇-连接剂-谷胱甘肽共轭物的组合物，通过克服血脑屏障（BBB）进入中枢神经系统的屏障入口，包括这些组合物的胶束和脂质体形式。此外，还公开了通过给予这些组合物治疗受试者的方法。
• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF
  申请人：Barre Lionel

  公开号：US20080021070A1

  公开（公告）日：2008-01-24

  The invention relates to compounds of formula (I): Wherein Z, R 3 to R 9 are as described herein. The invention also relates to methods of preparation of compounds of formula (I) and intermediates thereof. The compounds of this invention are active at CB1 cannabinoid receptor site, and are therefore, useful as pharmaceutical agents in treating a variety of diseases caused by the effects of CB1 cannabinoid receptors.

  这项发明涉及式(I)的化合物： 其中Z，R3至R9如本文所述。该发明还涉及制备式(I)化合物及其中间体的方法。本发明的化合物在CB1大麻素受体位点具有活性，因此在治疗由CB1大麻素受体效应引起的各种疾病中作为药用剂是有用的。
• 1,5-DIARYLPYRROLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS
  申请人：BARTH Francis

  公开号：US20080015245A1

  公开（公告）日：2008-01-17

  The invention relates to compounds having formula (I): Wherein X, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined herein. The invention also relates to a method of preparing said compounds and to die application thereof in therapeutics.

  该发明涉及具有以下结构式（I）的化合物：其中X，R1，R2，R3，R4，R5和R6如本文所定义。该发明还涉及一种制备所述化合物的方法以及在治疗中的应用。
• Compositions and Methods for Cellular Imaging and Therapy
  申请人：Yang J. David

  公开号：US20070248537A1

  公开（公告）日：2007-10-25

  The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits and methods for imaging and therapy involving N 4 compounds and derivatives.

  本发明一般涉及化学和放射性核素成像领域。更具体地，涉及涉及N4化合物及其衍生物的成分、试剂盒和成像和治疗方法。